id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy_to_NEW:overall_survival_advanced_gej_cancer
name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment â†’ Overall Survival in Advanced Gastric/Gastroesophageal
  Junction Cancer
from_node:
  node_id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy
  node_name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment
to_node:
  node_id: NEW:overall_survival_advanced_gej_cancer
  node_name: Overall Survival in Advanced Gastric/Gastroesophageal Junction Cancer
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Administration of immune checkpoint inhibitors (ICI) blocks inhibitory signals on T-cells (e.g.,
  PD-1/PD-L1 pathway)'
- 'Step 2: T-cell activation and proliferation enhances anti-tumor immune response'
- 'Step 3: Concurrent chemotherapy induces tumor cell death and antigen release, further stimulating immune
  recognition'
- 'Step 4: Combined immunogenic and cytotoxic effects lead to greater tumor control'
- 'Step 5: Improved tumor control translates to extended overall survival'
evidence:
  quality_rating: A
  n_studies: 5
  primary_citation: 'Lianghui Zhang et al. 2024. "Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line
    Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis."
    https://doi.org/10.1177/15330338241273286'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 5 randomized controlled trials
  - Studies involving 2,814 patients with advanced G/GEJ cancer
  - Trials comparing ICI plus chemotherapy versus chemotherapy alone as first-line treatment
  doi: 10.1177/15330338241273286
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Combination of immune checkpoint inhibitors with chemotherapy as first-line treatment significantly
  improves overall survival in patients with advanced gastric or gastroesophageal junction cancer compared
  to chemotherapy alone, with a 14% reduction in hazard of death.
quantitative_effects:
  effect_size:
    value: 0.86
    type: hazard_ratio
    ci_lower: 0.78
    ci_upper: 0.94
  p_value: 0.002
  sample_size: 2814
structural_competency:
  equity_implications: Access to novel immunotherapy treatments is a structural determinant of cancer
    outcomes. Disparities in access to ICI therapy may exist based on healthcare coverage, geographic
    proximity to cancer centers, and socioeconomic status. Ensuring equitable access to these treatments
    is critical for reducing cancer outcome disparities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.896000'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
